NSE: ABBOTINDIA | BSE: 500488

Expensive Performer

Download real time

30990.00 60.00 (0.19%)

3,306 NSE+BSE Volume

NSE 17 Sep, 2025 2:34 PM (IST)

65,851.6

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Abbott India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ABBOTINDIA, BSE:500488 Abbott India Ltd.

Abbott India Ltd.

07 Aug 2021

30990.00

0.19%

Abbott India

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

The company's top five brands - (Duphaston gynaecological, Thyronorm thyroid, Udiliv, Duphalac both GI and Vertin- CNS) together posted revenue CAGR of ~13% in March 2017-21 (MAT basis) Abbott has 140+ brands in segments of women's health, gastroenterology,...

Abbott India Ltd. is trading below its 30 day SMA of 32115.2

Abbott India Ltd.

19 May 2021

30990.00

0.19%

Result Update:Abbott India

Hold: Abbott India Ltd.

Target

Axis Direct

It is expected that competition to the Duphaston brand and stable volume in Thyronorm could result in lower revenue in upcoming quarters for Abbott India. We, therefore, recommend HOLD' on the stock with a target price of Rs 15,800/share.

Abbott India Ltd. is trading above its 200 day SMA of 30653.8

Abbott India Ltd.

19 May 2021

30990.00

0.19%

Abbott India

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Covid-19 related disturbances notwithstanding, companies from the pharma MNC staple like Abbott continue to generate investor's interest with robust and sustainable business model backed by stable growth, debt-free b/s, favourable market dynamics with doctor prescription stickiness and lower perceived risk factors. We continue to believe in Abbott's strong growth track in power brands and capability in new launches on a fairly consistent basis (+100 launches in the last 10 years). We maintain BUY and arrive at a target price of | 19235 (vs. earlier | 19065)...

Abbott India Ltd. has an average target of 35626.00 from 3 brokers.

Abbott India Ltd.

10 Feb 2021

30990.00

0.19%

Result Update:Abbott India

Hold: Abbott India Ltd.

Recommendation Target

Axis Direct

We reduce earnings by 1.4% and -4.5% for FY22E and FY23E respectively and recommend Hold with target price of Rs 15,700.

Abbott India Ltd. is trading below its 30 day SMA of 32115.2

Abbott India Ltd.

13 Nov 2020

30990.00

0.19%

Result Update:Abbott India

Buy: Abbott India Ltd.

Axis Direct

We expect revenue and PAT CAGR of 10.6% and 14.0% over the period FY20-FY23E and recommend BUY with target price of INR 18,500.

Abbott India Ltd. has an average target of 35626.00 from 3 brokers.

Abbott India Ltd.

17 Aug 2020, 12:00AM

30990.00

0.19%

Pick of the Week:17 AUG 2020

Buy: Abbott India Ltd.

Axis Direct

Abbott India Ltd' (AIL) strategy of Going Digital and Services beyond the pill is the key differentiator and game changer for the company. AIL' continuous endeavour to move from awareness to compliance to lifestyle modification has resulted in its success in the industry.

Abbott India Ltd. is trading below its 30 day SMA of 32115.2

Abbott India Ltd.

09 Jun 2020

30990.00

0.19%

Abbott India

Buy: Abbott India Ltd.

Recommendation Target

ICICI Securities Limited

Covid-19 related disturbances notwithstanding (likely to impact Q1FY21), companies from the pharma MNC staple like Abbott continue to generate investor's interest with robust and sustainable business model backed by stable growth, debt-free B/S, favourable market dynamics with doctor prescription stickiness and lower perceived risk factors. We continue to believe in Abbott's strong growth track in power brands and capability of new launches on a fairly consistent basis (+100 launches in the last 10 years). We upgrade the stock from HOLD to BUY and arrive at a target...

Abbott India Ltd. is trading above its 200 day SMA of 30653.8

Abbott India Ltd.

01 Jun 2020

30990.00

0.19%

Ashika - Stock Picks - Abbott India Ltd. - June 2020

Buy: Abbott India Ltd.

Target

Ashika Research

the expert clinical support to customer need. Company derives 63% revenue from brands and 37% from Insulin. Company's top 10 brands...

Abbott India Ltd. is trading below its 30 day SMA of 32115.2

Abbott India Ltd.

20 Apr 2020

30990.00

0.19%

Abbott India

Hold: Abbott India Ltd.

Recommendation Target

ICICI Securities Limited

On the business front, despite the nationwide lockdown, domestic growth is expected to remain more or less stable. Exports growth, barring for one or two months due to congestion in all major ports globally, is also expected to remain strong due to 1) currency benefit, 2) slowdown in competition due to delay in new approvals that will be beneficial for existing players and 3) expected demand continuum across the world despite Covid-19. Some windfall is also expected in some critical productsa case in point is Hydroxychloroquine, a malaria drug that is likely to be repurposed as a prophylaxis for Covid-19 treatment in some cases....

Abbott India Ltd. is trading above its 200 day SMA of 30653.8

Is Abbott India Ltd. worth buying?

309 Votes:

Buy 79.29%

Sell 10.68%

Hold 10.03%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf